Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
February 23, 2009
- NDAs Pending or Expected Soon for 3 Blockbuster Candidates: Novartis
February 16, 2009
- Chugai to Apply for 5 Products in 2009
February 16, 2009
- Takeda Starts PI in Japan for DPP-4 Inhibitor + Actos Combination
February 16, 2009
- Eli Lilly Japan to Conduct More PI Clinical Trials in Japan
February 16, 2009
- Astellas Has Strongest Image: NPhA Survey
February 16, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 16, 2009
- Council Recommends Health Insurance Coverage for KRAS Gene Mutation Tests
February 16, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 16, 2009
- PMDA to Take More PE-Based Post-Marketing Safety Measures
February 16, 2009
- Draft Guidance for Biosimilars Explained
February 16, 2009
- Strattera Recommended for Approval for AD/HD
February 16, 2009
- Astellas Withdraws NDA for Controlled-Release Formulation of Tacrolimus in US
February 16, 2009
- FDA Advisory Committee Recommends Approval of Prasugrel
February 16, 2009
- Ministerial Ordinance Issued Prohibiting Online Sale of Class 1, 2 OTC Drugs
February 16, 2009
- Takeda Obtains Approval for Lansoprazole's Successor in US
February 16, 2009
- Low Recognition Rate for AMD: Novartis Survey
February 16, 2009
- New GL Recommends Hp Eradication for All Hp-Related Diseases
February 16, 2009
- Japan's Most Admired Pharma Companies in 2008 P. Reed Maurer
February 16, 2009
- BD Expands Portfolio for Uterocervical Cancer Cytodiagnosis System
February 16, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…